The Safety of Oral Versus Transdermal Estrogen

Denise Black, MD, FRCSC


Menopause. 2020;27(11):1328-1329. 

In This Article

Women at Increased Risk for Venous Thromboembolism

Risks for VTE include hereditary risk (familial prothrombotic mutations) and constitutional risks such as advancing age, obesity, and prior history of a VTE event. Age is an important factor, with VTE risk increasing exponentially after age 50 years. Women with a personal history of VTE have an increased risk of recurrence, even without a prothrombotic mutation.[2] In women with increased risk of a VTE, transdermal estrogen seems to be a safer choice than oral, based on observational data.[3]